Funding Milestone: Calla Lily Clinical Care Secures £180,000 in Angel Round for Innovative Vaginal Drug Delivery Platform

Calla Lily Clinical Care is excited to announce that we have successfully raised £180,000 in our latest funding round, a significant milestone that will propel our mission forward. As a pioneering British medical device startup, we are dedicated to developing a leak-free, convenient, and dosage-confident delivery platform for vaginally-delivered medications. Our initial focus lies in addressing the critical need for effective and patient-friendly delivery of progesterone, particularly for women navigating the challenges of miscarriage prevention and IVF treatment. The growing prescription rates of progesterone, spurred by the updated NICE guidelines in November 2021, underscore the urgency for innovative solutions in this space. This funding will enable us to advance our product development and expand our clinical trials, ensuring that our platform meets the needs of patients facing emotional and physical hurdles during their fertility journey. Furthermore, we are also looking toward the future, with subsequent applications of our technology targeted at treatments for menopause and the vaginal microbiome, areas in need of modern solutions. With our patented delivery technology already receiving FDA clearance and being recognized as one of TIME magazine’s Best Inventions of the Year, we are confident that this investment will enhance our capacity to create impactful healthcare solutions. We would like to extend our heartfelt gratitude to our investors for their trust and support as we continue to drive forward in revolutionizing women's health care.